A Win For Atreca, Inc.
Mon, Jan 29, 2024 at 07:16 PM
Atreca, Inc. (BCEL:NASDAQ) shot up at $0.33, representing a gain of 35.7%. On Mon, Jan 29, 2024, BCEL:NASDAQ touched a New 2-Week High of $0.33. From Tue, Jan 16, 2024, the stock recorded 44.44% Up Days and 50.00% Green Days
The stock spiked on Thu, Jan 18, 2024 at $0.39 with a volume of 21M+.
About Atreca, Inc. (BCEL:NASDAQ)
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Top 10 Gainers:
- OneMedNet Corp. (ONMD:NASDAQ), 156.27%
- Palisade Bio Inc. (PALI:NASDAQ), 83.21%
- FibroGen, Inc. (FGEN:NASDAQ), 82.71%
- NexImmune Inc. (NEXI:NASDAQ), 73.83%
- Vinco Ventures Inc. (BBIG:NASDAQ), 55%
- Rail Vision Ltd. (RVSN:NASDAQ), 54.63%
- Connexa Sports Technologies Inc. (CNXA:NASDAQ), 43.69%
- View Inc. (VIEW:NASDAQ), 41.03%
- Selina Hospitality PLC (SLNA:NASDAQ), 38.04%
- Atreca, Inc. (BCEL:NASDAQ), 35.7%